Compare Enovix Corporation (ENVX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Sana Biotechnology Inc — how do they compare? Enovix Corporation trades at $4.51 (market cap $1.06B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Enovix Corporation and Sana Biotechnology Inc are close in size by market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals.
| ENVX | SANA | |
|---|---|---|
Market Cap | $1.06B | $1.13B |
Sector | Technology | Health |
52-Week High | $13.19 | $5.92 |
52-Week Low | $3.68 | $2.68 |
Enterprise Value | $1.07B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $4.73, up 1.94% with a bullish technical signal despite negative profitability metrics. The company shows consistent earnings beats but operates at significant losses with a -499.64% net income margin. Recent positive developments include the appointment of a former Apple executive as COO and upcoming Q2 2026 earnings on August 12, 2026.
Analyst consensus remains strongly bullish with a $12.38 price target (162% upside), though execution risks are high given cash burn and negative margins. The stock offers speculative growth potential in advanced battery technology but requires careful risk management due to ongoing operational losses.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
